With more people at risk for cardiovascular disease than ever before, the Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab® is advancing a prevention-focused approach for heart disease and associated metabolic conditions.
Cardiovascular disease (CVD) is strongly associated with type 2 diabetes (T2DM), chronic kidney disease (CKD), and nonalcoholic fatty liver disease (NAFLD). Through significant investments in novel technology, the Cleveland HeartLab is fostering innovation to detect these conditions in their early stages, providing the opportunity for stage-targeted intervention and improved clinical outcomes.
- Cardiovascular disease is the leading cause of death for individuals who have T2DM,3 stage 4-5 CKD,4 and NAFLD.5
- Those who have T2DM have a 2 to 3 times higher risk of fatal coronary heart disease.6
- Nearly 40% of persons who have diabetes and more than 30% of those who have hypertension also have CKD.7 The leading causes of end-stage renal disease are diabetes and hypertension.8
- More than 75% of those who have T2DM have NAFLD.9